LEADER 00934cam0 22002771 450 001 SOBE00021700 005 20120123093917.0 010 $a8870422658 100 $a20120123d1984 |||||ita|0103 ba 101 $aita 102 $aIT 200 1 $a<>amaro della feudalità$ela devoluzione di Arnone e la questione feudale a Napoli alla fine del '700$fAnna Maria Rao 210 $aNapoli$cGuida$d1984 215 $a382 p.$d21 cm 225 2 $aEsperienze$v119 410 1$1001LAEC00017573$12001 $a*Esperienze$v119 700 1$aRao$b, Anna Maria$3AF00018482$4070$09780 801 0$aIT$bUNISOB$c20120123$gRICA 850 $aUNISOB 852 $aUNISOB$j900$m155652 912 $aSOBE00021700 940 $aM 102 Monografia moderna SBN 941 $aM 957 $a900$b005204$gSI$d155652$rdono$1catenacci$2UNISOB$3UNISOB$420120123093922.0$520120123094052.0$6catenacci 996 $aAmaro della feudalità$9105406 997 $aUNISOB LEADER 04711nam 2200649Ia 450 001 9910456053203321 005 20200520144314.0 010 $a1-280-24677-4 010 $a9786610246779 010 $a0-309-58152-4 010 $a0-585-14491-5 035 $a(CKB)110986584750692 035 $a(EBL)3376089 035 $a(SSID)ssj0000266426 035 $a(PQKBManifestationID)11206711 035 $a(PQKBTitleCode)TC0000266426 035 $a(PQKBWorkID)10301177 035 $a(PQKB)11591059 035 $a(MiAaPQ)EBC3376089 035 $a(Au-PeEL)EBL3376089 035 $a(CaPaEBR)ebr10055083 035 $a(CaONFJC)MIL24677 035 $a(OCoLC)923261025 035 $a(EXLCZ)99110986584750692 100 $a19851205d1985 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aVaccine supply and innovation$b[electronic resource] /$fDivision of Health Promotion and Disease Prevention, Institute of Medicine 210 $aWashington, D.C. $cNational Academy Press$d1985 215 $a1 online resource (210 p.) 225 1 $aPublication IOM ;$vno. 85-02 300 $aDescription based upon print version of record. 311 $a0-309-03544-9 320 $aIncludes bibliographical references. 327 $a""Vaccine Supply and Innovation""; ""Copyright""; ""Preface""; ""Contents""; ""Vaccine Supply and Innovation""; ""1 Summary""; ""OVERVIEW""; ""VACCINE AVAILABILITY: MAJOR BARRIERS AND IMPEDIMENTS""; ""Impediments to Vaccine Innovation""; ""ECONOMIC CHARACTERISTICS OF THE VACCINE INDUSTRY""; ""VACCINE INJURY""; ""THE LEGAL SITUATION AND ITS CONSEQUENCES""; ""CONSEQUENCES OF THE STATE OF VACCINE INJURY LIABILITY LAW FOR VACCINE PRODUCTION AND INNOVATION""; ""A NATIONAL VACCINE COMMISSION""; ""COMPENSATION AND LIABILITY FOR VACCINE-RELATED INJURY""; ""2 Vaccines: Past, Present, and Future"" 327 $a""TYPES OF IMMUNIZATION""""HISTORY OF IMMUNIZATION""; ""THE PRESENT""; ""Development of Vaccines and Recommendations for Vaccine Use""; ""THE FUTURE""; ""REFERENCES AND NOTES""; ""3 Vaccine Availability: Concerns, Barriers, and Impediments""; ""CONCERNS ABOUT THE CURRENT SITUATION""; ""Supply""; ""Stockpiling of Vaccines""; ""Problems with Sole Reliance on Foreign Manufacturers""; ""Federal Action to Ensure Vaccine Supply""; ""BARRIERS AND IMPEDIMENTS TO VACCINE INNOVATION""; ""Identification of Need and Establishing Priorities"" 327 $a""Establishing the Technical Feasibility of Vaccine Development""""Economic Disincentives to Innovation and Production""; ""Factors Influencing the Market for Vaccines""; ""VACCINE UTILIZATION""; ""System Factors""; ""Client Factors""; ""Provider Factors""; ""CONCLUSIONS""; ""Barriers and Impediments to Vaccine Innovation""; ""REFERENCES AND NOTES""; ""4 Economic Aspects of Vaccine Innovation and Manufacturing""; ""POTENTIAL CAUSES OF INDUSTRY DECLINE""; ""Property Rights and Innovation""; ""Regulation""; ""Market Size""; ""Liability and Risk""; ""DESCRIPTIVE STATISTICS"" 327 $a""The Market and Participants""""Pricing""; ""Research and Development""; ""CONCLUSIONS""; ""REFERENCES AND NOTES""; ""5 Vaccine Injury""; ""The Pertussis Controversy""; ""Identifying Individuals at High Risk of Adverse Effects""; ""VACCINES USED IN CHILDHOOD""; ""Pertussis Vaccine""; ""Diphtheria Toxoid""; ""Tetanus Toxoid""; ""Poliomyelitis Vaccines""; ""Measles Vaccine""; ""Rubella Vaccine""; ""Mumps Vaccine""; ""VACCINES FOR ADULTS""; ""Influenza Vaccines""; ""Pneumococcal Vaccines""; ""Meningococcal Vaccines""; ""Rabies Vaccine""; ""Hepatitis B Vaccine""; ""SUMMARY"" 327 $a""REFERENCES AND NOTES""""6 Liability for the Production and Sale of Vaccines ""; ""STATE OF THE LAW""; ""Experience From the Swine Flu Vaccination Program""; ""Recent Trends""; ""The Issue of Punitive Damages""; ""Summary of the Legal Situation""; ""CONSEQUENCES OF THE STATE OF VACCINE INJURY LIABILITY LAW FOR VACCINE PRODUCTION AND INNOVATION""; ""REFERENCES AND NOTES""; ""7 An Approach to the Problems of Communication, Coordination, and Collaboration in Vaccine Policy""; ""HISTORICAL BACKGROUND""; ""THE EXISTING STRUCTURE""; ""Federal Agency Interactions"" 327 $a""Public-Private Sector Interactions"" 410 0$aIOM publication ;$v85-02. 606 $aVaccines$xResearch 606 $aImmunization 608 $aElectronic books. 615 0$aVaccines$xResearch. 615 0$aImmunization. 676 $a338.47615372 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910456053203321 996 $aVaccine supply and innovation$92177201 997 $aUNINA LEADER 01234nam0 22002653i 450 001 VAN0112123 005 20171114085724.881 010 $a978-88-8234-346-0 100 $a20171114d2006 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| ||||| 200 1 $aˆ"L'‰imputato non è colpevole"$eatti del processo 'Talaat Pascia'$erapporto stenografico sul dibattimento a carico dello studente armeno Soghomon Tehlirian, imputato dell'omicidio di Talaat Pascià dalla Corte d'assise del 3. Tribunale regionale di Berlino. Faldone C.J$h22/21$i2-3 giugno 1921$fprefazione di Gérard Chaliand 210 $aLecce$cArgo$d2006 215 $a201 p.$d23 cm. 410 1$1001VAN0051781$12001 $aˆIl ‰pianeta scritto$1210 $aLecce$cArgo.$v71 620 $dLecce$3VANL000073 702 1$aChaliand$bGérard$3VANV021623 712 $aArgo$3VANV109096$4650 801 $aIT$bSOL$c20230616$gRICA 899 $aBIBLIOTECA DEL DIPARTIMENTO DI GIURISPRUDENZA$1IT-CE0105$2VAN00 912 $aVAN0112123 950 $aBIBLIOTECA DEL DIPARTIMENTO DI GIURISPRUDENZA$d00CONS XXI.Eg.49 $e00UBG2233 20171114 996 $aImputato non è colpevole"$91522015 997 $aUNICAMPANIA